AP
BMY icon

Arlington Partners’s Bristol-Myers Squibb BMY Stock Holding History

Arlington Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
4,854
+877
+22% +$50.4K 0.51% 18
2026
Q1 		$241K Buy
+3,977
New +$232K 0.48% 24
2025
Q4 		– Sell
-105,711
Closed -$4.77M – 11
2025
Q3 		$4.77M Buy
105,711
+10,382
+11% +$485K 1.65% 42
2025
Q2 		$4.41M Buy
95,329
+14,532
+18% +$713K 1.63% 35
2025
Q1 		$4.93M Hold
80,797
– – 1.93% 6
2024
Q4 		$4.57M Sell
80,797
-10,000
-11% -$559K 1.77% 6
2024
Q3 		$4.7M Buy
90,797
+12,491
+16% +$586K 1.84% 5
2024
Q2 		$3.25M Buy
78,306
+15,773
+25% +$706K 1.61% 26
2024
Q1 		$3.39M Buy
62,533
+60,558
+3,066% +$3.08M 1.73% 13
2023
Q4 		$101K Buy
+1,975
New +$104K 0.03% 102
2023
Q3 		– Sell
-1,692
Closed -$108K – 384
2023
Q2 		$108K Sell
1,692
-182
-10% -$12.2K 0.02% 236
2023
Q1 		$130K Sell
1,874
-317
-14% -$22.4K 0.02% 170
2022
Q4 		$158K Buy
2,191
+404
+23% +$30.5K 0.03% 109
2022
Q3 		$127K Sell
1,787
-172
-9% -$12.5K 0.05% 116
2022
Q2 		$151K Buy
1,959
+643
+49% +$49K 0.05% 119
2022
Q1 		$96K Buy
1,316
+74
+6% +$4.97K 0.03% 183
2021
Q4 		$77K Sell
1,242
-1,019
-45% -$59.8K 0.02% 230
2021
Q3 		$134K Buy
2,261
+1,579
+232% +$104K 0.04% 146
2021
Q2 		$46K Hold
682
– – 0.02% 201
2021
Q1 		$43K Hold
682
– – 0.02% 257
2020
Q4 		$42K Hold
682
– – 0.02% 113
2020
Q3 		$41K Hold
682
– – 0.02% 107
2020
Q2 		$40K Buy
682
+593
+666% +$35.5K 0.02% 110
2020
Q1 		$5K Sell
89
-400
-82% -$24.4K ﹤0.01% 182
2019
Q4 		$31K Buy
489
+89
+22% +$5.1K 0.02% 151
2019
Q3 		$20K Hold
400
– – 0.01% 139
2019
Q2 		$18K Sell
400
-1,169
-75% -$54.5K 0.01% 181
2019
Q1 		$75K Buy
1,569
+169
+12% +$8.42K 0.05% 106
2018
Q4 		$73K Buy
1,400
+400
+40% +$21.5K 0.05% 102
2018
Q3 		$62K Buy
+1,000
New +$59.3K 0.04% 118

Other funds holding BMY

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
ORIO
Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Arlington Partners's BMY Position: Q2 2026 in Review

Arlington Partners increased its Bristol-Myers Squibb (BMY) stake by 22% in Q2 2026, buying an estimated $50.4K and bringing the position to 4,854 shares worth $280K. The position accounts for 0.51% of the portfolio, ranked #18.

Arlington Partners first reported a position in BMY in Q3 2018 and has held it in 30 quarters since. The position peaked at $4.93M in Q1 2025. 440 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Arlington Partners held 4,854 shares of Bristol-Myers Squibb worth $280K as of Q2 2026.
  • Arlington Partners bought 877 Bristol-Myers Squibb shares in Q2 2026, an estimated $50.4K.
  • Bristol-Myers Squibb made up 0.51% of Arlington Partners's portfolio in Q2 2026, its #18 holding.
  • Arlington Partners first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 30 quarters since.
  • Arlington Partners's Bristol-Myers Squibb position peaked at $4.93M in Q1 2025.
  • 440 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Arlington Partners's 13F filing for Q2 2026, filed 7 Jul 2026.